Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

A precision medicine approach has been successfully applied in medical oncology for the treatment of non-small-cell lung cancer (NSCLC) through the identification of targetable driver molecular aberrations; activating mutations of epidermal growth factor receptor (EGFR) are the most common. Osimerti...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Noia, V., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., Ceresoli, G.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506968/
https://www.ncbi.nlm.nih.gov/pubmed/34634633
http://dx.doi.org/10.1016/j.esmoop.2021.100280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506968/
https://www.ncbi.nlm.nih.gov/pubmed/34634633
http://dx.doi.org/10.1016/j.esmoop.2021.100280

Ejemplares similares